Skip to main content
رجوع
Watch Compare

Inhibikase Therapeutics, Inc.

جودة البيانات: 83%
IKT
NASDAQ Manufacturing Chemicals
KWD 1.70
▼ KWD 0.09 (-5.03%)
6 months return
—
Momentum
Neutral
ROE
-63.10%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-63.10%
أقل من متوسط القطاع (-54.68%)
ROIC-53.69%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio11.73
Interest Coverage-13.99

التقييم

PE (TTM|NTM)
-4.64 | -4.71
أقل من متوسط القطاع (-1.49)
P/B Ratio3.07
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -27.80 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

8 محللين
Buy
+238.2%
upside to target
الحالي
KWD 1.70
Consensus Target
KWD 5.75
KWD 3.00
أدنى
KWD 8.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-4.71
ربحية السهم المستقبلية
-KWD 0.38
الإيرادات المقدّرة
333,330.0

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.09 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 0.15 -KWD 0.11 -KWD 0.13 -KWD 0.09 — —
Estimate -KWD 0.10 -KWD 0.08 -KWD 0.13 -KWD 0.12 -KWD 0.09 -KWD 0.09
المفاجأة -57.89% -37.50% 0.00% +23.94% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -63.10% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -48.26 M
ROE -63.10% ROA -57.30%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -27.80 M
ROIC -53.69% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 11.73
Debt / Equity N/A Current Ratio 11.73
Interest Coverage -13.99 Asset Turnover N/A
Working Capital 71.84 M Tangible Book Value 72.90 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -4.64 · EV/EBITDA: N/A
P/E Ratio -4.64 Forward P/E -4.71
P/B Ratio 3.07 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 671.39 Fwd Earnings Yield N/A
FCF Yield -12.42%
Market Cap 223.80 M Enterprise Value 223.80 M

Per Share

EPS: -0.49 · FCF/Share: -0.21
EPS (Diluted TTM) -0.49 Revenue / Share N/A
FCF / Share -0.21 OCF / Share -0.21
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 57.61% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 57.61%
SBC-Adj. FCF -38.61 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2023 FY2024 FY2022 FY2021
Revenue — 260,501.0 0.0 123,440.0 3.10 M
Net Income -48.26 M -19.03 M -27.52 M -18.05 M -14.79 M
EPS (Diluted) -0.49 -3.57 -1.16 -0.72 —
Gross Profit — — — — —
Operating Income -51.97 M -20.09 M -28.59 M -18.13 M -14.77 M
EBITDA — — — — —
R&D Expenses 29.79 M 13.62 M 17.21 M 12.03 M 11.36 M
SG&A Expenses 23.56 M 6.73 M 11.38 M 6.22 M 6.51 M
D&A — — — — —
Interest Expense 3.72 M 1.06 M 1.07 M 74,453.0 19,923.0
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2023 FY2024 FY2022 FY2021
Total Assets 181.20 M 14.51 M 98.60 M 24.94 M 42.47 M
Total Liabilities 8.30 M 3.53 M 3.73 M 3.90 M 4.05 M
Shareholders' Equity 172.90 M 10.98 M 94.87 M 21.04 M 38.42 M
Total Debt — 381,784.0 — — 248,911.0
Cash & Equivalents 178.80 M 9.17 M 56.50 M 7.19 M —
Current Assets 180.11 M 14.21 M 98.45 M 24.37 M —
Current Liabilities 8.30 M 3.44 M 3.73 M 3.70 M 4.05 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -4.6 -1.5
P/B 3.1 1.6
ROE % -63.1 -54.7
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

ETFs Holding This Stock
IRSIX IRSIX
0.01% weight
IIRSX IIRSX
0.01% weight
IRCIX IRCIX
0.01% weight
VVICX VVICX
0.00% weight
IRSSX IRSSX
0.00% weight